Rafael Holdings, Inc. has secured an exclusive licensing agreement with the Massachusetts Institute of Technology for U.S. Patent No. 12285440, which pertains to the application of cyclodextrins in treating Alzheimer’s disease in patients with the ApoE4 genetic variant. This licensing aims to bolster Rafael Holdings’ intellectual property surrounding Trappsol Cyclo, specifically targeting the significant subset of Alzheimer’s patients—estimated at 50 to 70 percent—who carry this variant, known for its association with earlier onset sporadic cases.

The significance of this development lies in the therapeutic potential of Trappsol Cyclo, which operates through a mechanism that enhances cholesterol transport between central nervous system cells. This pathway is critical, as it is linked to the underlying amyloid and tau pathologies prevalent in ApoE4-positive patients. Preclinical studies have demonstrated promising results, including improved cholesterol delivery in the CNS, reduced tau pathology, and enhanced cognitive functions such as learning and memory in murine models. These findings suggest a viable route for addressing the neurodegenerative processes associated with Alzheimer’s in a genetically vulnerable population.

The implication of this licensing agreement is substantial for the field of aging and neurodegeneration research. It not only strengthens the intellectual property landscape for cyclodextrin-based therapies but also sets the stage for Phase 3 clinical trials, with results from the Transport NPC study expected in the third quarter of 2026. This timeline could accelerate the development of targeted therapies for a significant portion of Alzheimer’s patients, potentially reshaping treatment paradigms and drug development strategies within the field.

Source: longevity.technology